Company news

Lexicon Pharmaceuticals, Inc. news in 2024

Lexicon Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

December 19, 2024

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

November 25, 2024

Lexicon Pharmaceuticals to Participate in December Investor Conferences

November 24, 2024

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

November 21, 2024

Lexicon Appoints Ivan H. Cheung to Board of Directors

November 19, 2024

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

November 13, 2024

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

November 5, 2024

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

November 4, 2024

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

November 4, 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

November 3, 2024

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

October 30, 2024

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

October 22, 2024

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

October 21, 2024

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

October 15, 2024

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

September 26, 2024

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

September 15, 2024

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

September 9, 2024

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

September 2, 2024

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

September 2, 2024

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

August 20, 2024

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

August 12, 2024

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

August 6, 2024

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

July 31, 2024

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

July 24, 2024

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

July 15, 2024

New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

July 14, 2024

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

July 7, 2024

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

June 20, 2024

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

June 18, 2024

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

June 17, 2024

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

June 13, 2024

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

May 28, 2024

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

May 13, 2024

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

May 8, 2024

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

April 28, 2024

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024

April 28, 2024

Lexicon Pharmaceuticals to Host 2024 Investor Day

April 17, 2024

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

March 24, 2024

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

March 11, 2024

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

March 10, 2024

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

March 10, 2024

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

March 10, 2024

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

Calls in 2024

Decks in 2024